PNC FINANCIAL SERVICES GROUP, INC.
Position in PLX — Protalix BioTherapeutics, Inc.
CIK 713676
Pittsburgh, PA
Position in PLX
as of Jun 30, 2026
· filed Aug 7, 2026
Position Value
$46
+$3 QoQ
Shares Held
20
0.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#98
of 101 holders
Holding Since
Dec 2023
6 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in PLX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026PNC FINANCIAL SERVICES GROUP, INC. holds $113,274,406 across 262 Biotechnology names. PLX ranks #258 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
69,358 | $34,452,195 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
16,662 | $10,389,420 | |
| 3 | TECH |
BIO-TECHNE Corp
|
77,074 | $5,445,277 | |
| 4 | MRNA |
Moderna, Inc.
|
70,829 | $4,960,151 | |
| 5 | TGTX |
Tg Therapeutics, Inc.
|
89,646 | $4,925,149 | |
| 6 | DNTH |
Dianthus Therapeutics, Inc. /DE/
|
39,473 | $3,847,827 | |
| 7 | INCY |
Incyte Corp
|
32,777 | $3,715,597 | |
| 8 | ARGX |
Argenx SE
|
3,967 | $3,680,460 |
All Filings in PLX
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $46 | 20 | Shares | Defined | 2026-08-07 | |
| 2026-03-31 | $43 | 20 | Shares | Defined | 2026-05-08 | |
| 2025-12-31 | $36 | 20 | Shares | Defined | 2026-02-06 | |
| 2025-09-30 | $77 | 35 | Shares | Defined | 2025-11-07 | |
| 2024-06-30 | $1,659 | 1,418 | Shares | Defined | 2024-08-09 | |
| 2023-12-31 | $33 | 19 | Shares | Defined | 2024-03-22 | |
| No filing history on record for this holder in this stock. | ||||||